5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic substance which can be synthetically produced, and found in plants, as well as in the secretion of the Incilius Alvarius toad (also known as Bufo Alvarius). Previous research has demonstrated the prospective therapeutic potential of 5-methoxy-N,N-dimethyltryptamine, however more research is warranted. While the common route of administration appears to be vaporization, intramuscular injection is also being used – but in much lower rates. Furthermore, anecdotal reports online have described a poorly understood phenomenon following use in naturalistic settings which has been termed re-activation. Specifically, reactivation refers to the re-experiencing (“flashback”) of some of the effects induced by 5-MeO-DMT intake after the drug’s acute effects have worn off. Given that the incidence of the re-activation phenomenon could represent a potential barrier to clinical research with this novel drug, further assessment of this phenomenon is needed. Thus, this study aimed to assess whether the occurrence of the phenomenon of “re-activation” was associated with a specific route of drug administration. Additionally, we were interested in examining other similarities and/or differences between the two routes of administration with regard to (re)dose, time of onset, perceived somatic release during the session, as well as satisfaction with life and ratings of the psychedelic experience. Using internet-based advertisements, 27 respondents completed an online-based survey. A summary of the preliminary results will be presented.